Mathematical Modelling Long-Term Effects of Replacing Prevnar7 with Prevnar13 on Invasive Pneumococcal Diseases in England and Wales

作者: Yoon Hong Choi , Mark Jit , Stefan Flasche , Nigel Gay , Elizabeth Miller

DOI: 10.1371/JOURNAL.PONE.0039927

关键词:

摘要: England and Wales recently replaced the 7-valent pneumococcal conjugate vaccine (PCV7) with its 13-valent equivalent (PCV13), partly based on projections from mathematical models of long-term impact such a switch compared to ceasing vaccination altogether. A compartmental deterministic model was used estimate parameters governing transmission infection competition between different groups serotypes prior introduction PCV13. The best-fitting were in an individual describe dynamics effects various options for programme change Wales. number scenarios conducted using (i) assumptions about invasive disease cases adjusted increasing trend incidence PCV7 Wales, (ii) range values representing serotype replacement induced by additional six Most considered suggest that use would cause increase incidence, while replacing PCV13 overall decrease. However, size this reduction largely depends level estimates over 20 years vaccination, around 5000–62000 IPD could be prevented stopping Despite inevitable uncertainty following PCV13, suggests all cases. Our results provide useful evidence benefits countries or considering as well data can evaluate cost-effectiveness switch.

参考文章(16)
Yoon Hong Choi, Mark Jit, Nigel Gay, Nick Andrews, Pauline A Waight, Alessia Melegaro, Robert George, Elizabeth Miller, None, 7-Valent Pneumococcal Conjugate Vaccination in England and Wales: Is It Still Beneficial Despite High Levels of Serotype Replacement? PLoS ONE. ,vol. 6, pp. e26190- ,(2011) , 10.1371/JOURNAL.PONE.0026190
Sara Boccalini, Chiara Azzari, Massimo Resti, Claudia Valleriani, Martina Cortimiglia, Emilia Tiscione, Angela Bechini, Paolo Bonanni, None, Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy. Vaccine. ,vol. 29, pp. 9521- 9528 ,(2011) , 10.1016/J.VACCINE.2011.10.013
Philippe De Wals, Steven Black, Ray Borrow, David Pearce, Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clinical Therapeutics. ,vol. 31, pp. 2152- 2169 ,(2009) , 10.1016/J.CLINTHERA.2009.10.014
Bjarne Robberstad, Carl R. Frostad, Per E. Akselsen, Kari J. Kværner, Aud K.H. Berstad, Economic evaluation of second generation pneumococcal conjugate vaccines in Norway Vaccine. ,vol. 29, pp. 8564- 8574 ,(2011) , 10.1016/J.VACCINE.2011.09.025
David R. Strutton, Raymond A. Farkouh, Stephanie R. Earnshaw, Sharon Hwang, Ulrike Theidel, Stathis Kontodimas, Rogier Klok, Sotiria Papanicolaou, Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands. Journal of Infection. ,vol. 64, pp. 54- 67 ,(2012) , 10.1016/J.JINF.2011.10.015
Hanna Rinta-Kokko, Ron Dagan, Noga Givon-Lavi, Kari Auranen, Estimation of vaccine efficacy against acquisition of pneumococcal carriage. Vaccine. ,vol. 27, pp. 3831- 3837 ,(2009) , 10.1016/J.VACCINE.2009.04.009
Kari Auranen, Juha Mehtälä, Antti Tanskanen, Margit S. Kaltoft, Between-Strain Competition in Acquisition and Clearance of Pneumococcal Carriage—Epidemiologic Evidence From a Longitudinal Study of Day-Care Children American Journal of Epidemiology. ,vol. 171, pp. 169- 176 ,(2010) , 10.1093/AJE/KWP351
Stefan Flasche, Albert Jan Van Hoek, Elizabeth Sheasby, Pauline Waight, Nick Andrews, Carmen Sheppard, Robert George, Elizabeth Miller, Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study PLOS Medicine. ,vol. 8, ,(2011) , 10.1371/JOURNAL.PMED.1001017
Elizabeth Miller, Nicholas J Andrews, Pauline A Waight, Mary PE Slack, Robert C George, Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study Lancet Infectious Diseases. ,vol. 11, pp. 760- 768 ,(2011) , 10.1016/S1473-3099(11)70090-1